NYSEARCA:IDNA iShares Genomics Immunology and Healthcare ETF (IDNA) Price, Holdings, & News $22.97 -0.84 (-3.53%) (As of 11/15/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartHoldingsOwnershipRatings About iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IDNA alerts:Sign Up Key Stats Today's Range$22.93▼$23.7050-Day Range$22.97▼$25.5352-Week Range$19.10▼$25.80Volume24,565 shsAverage Volume32,926 shsMarket Capitalization$134.37 millionAssets Under Management$136.15 millionDividend Yield0.61%Net Expense Ratio0.47%Aggregate RatingModerate Buy ETF OverviewThe iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.Read More… “This Changes Everything” - Trump Hands Millions Massive IRS Gift (Ad)Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…>> YES! Send Me My FREE Gold Guide! iShares Genomics Immunology and Healthcare ETF ExpensesTypeIDNATheme ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.47%0.57%0.55%0.51%0.52%Other Expenses0.00%0.57%0.49%0.57%0.53%Total Expense0.47%0.73%0.71%0.73%0.71%Fee Waiver0.00%-0.74%-0.52%-0.67%-0.57%Net Expense0.47%0.60%0.61%0.58%0.59% Receive IDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iShares Genomics Immunology and Healthcare ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address IDNA ETF News HeadlinesIshares Healthcare Innov Ucits Etf Acc Share Price (HEAL.MI)November 7, 2024 | lse.co.ukiShares S&P 500 Health Care Sector UCITS ETF USD (Acc) (IUHC.L)September 25, 2024 | finance.yahoo.com5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.November 17, 2024 | Traders Agency (Ad)iDNA Genomics Public LtdMay 18, 2024 | morningstar.comiShares Genomics Immunology and Healthcare ETF (IDNA)April 15, 2024 | finance.yahoo.comIDNA: Healthcare Dashboard For FebruaryFebruary 18, 2024 | seekingalpha.comSee More Headlines IDNA ETF - Frequently Asked Questions How have IDNA shares performed this year? iShares Genomics Immunology and Healthcare ETF's stock was trading at $23.01 at the start of the year. Since then, IDNA shares have decreased by 0.2% and is now trading at $22.97. View the best growth stocks for 2024 here. Who are iShares Genomics Immunology and Healthcare ETF's major shareholders? Top institutional shareholders of iShares Genomics Immunology and Healthcare ETF include Avior Wealth Management LLC (0.16%). How do I buy shares of iShares Genomics Immunology and Healthcare ETF? Shares of IDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of iShares Genomics Immunology and Healthcare ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that iShares Genomics Immunology and Healthcare ETF investors own include iShares Micro-Cap ETF (IWC), The RMR Group (RMR), Waste Connections (WCN), DiamondRock Hospitality (DRH), AUO (AUOTY), American Water Works (AWK) and Triple Flag Precious Metals (TFPM). Fund Details IssueriShares Fund NameiShares Genomics Immunology and Healthcare ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:IDNA Inception Date6/11/2019 Fund ManagerJennifer Hsui, Greg Savage, Paul Whitehead WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkNYSE FactSet Global Genomics and Immuno Biopharma Index CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings61 Fund Statistics Assets Under Management$136.15 million Average Daily Volume$0.00 Discount/Premium-0.08% Administrator, Advisor and Custodian AdministratorState Street Bank and Trust Company AdvisorBlackRock Fund Advisors CustodianState Street Bank and Trust Company DistributorBlackRock Investments, LLC Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerJane Street Options OptionableOptionable Options Volume1 Put Options1 Call Options2 Short Interest100 shs Miscellaneous Outstanding Shares5,850,000Beta1.14 Creation Unit50,000 Creation Fee$850.00 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Top 10 IDNA HoldingsGilead Sciences (NASDAQ:GILD)Holding Weight: 5.61%BeiGene, Ltd.Holding Weight: 5.52%Exelixis (NASDAQ:EXEL)Holding Weight: 5.20%Roche Holding AGHolding Weight: 4.90%Revolution Medicines (NASDAQ:RVMD)Holding Weight: 4.70%BioNTech (NASDAQ:BNTX)Holding Weight: 4.49%Incyte (NASDAQ:INCY)Holding Weight: 4.49%SanofiHolding Weight: 4.49%Sarepta Therapeutics (NASDAQ:SRPT)Holding Weight: 4.34%Takeda Pharmaceutical Company LimitedHolding Weight: 4.08%Full Holdings DetailsIDNA Sector ExposureIDNA Industry Exposure This page (NYSEARCA:IDNA) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares Genomics Immunology and Healthcare ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share iShares Genomics Immunology and Healthcare ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
